Phase III dosing defined for lixivaptan in autosomal dominant polycystic kidney disease Nov. 20, 2019
First placebo-controlled trial in renal scleroderma shows positive results for zibotentan Nov. 19, 2019
Sparsentan does not appear to have a negative effect on quality of life in FSGS patients Nov. 18, 2019
Results from SILK cohort evaluating tesevatinib in ADPKD patients presented at Kidney Week Nov. 15, 2019
RSS